Health care is a trillion-dollar industry because health is a global need. A trillion-dollar industry means plenty of companies making millions or billions of dollars annually in the health sector. With the surge of COVID-19, this industry has attracted plethora of investors to invest in healthcare stocks but many of them find it difficult to select the right stock at the right time. This is because many companies have claimed that they are working on vaccines and related products to cope with COVID-19 but only a few of them have found their way to commercialize their products. One should consider the fact that only COVID-19 is not the opportunity to invest in stocks but there are other health issues that demand a great amount of interest. So, investors need to do a large amount of homework before investing in any stock. Here are the few health care stocks that can attract investors in 2021.
Eli Lilly And Co (NYSE:LLY)
Eli Lilly and Company (LLY) is an American Pharmaceutical company that focuses on discovering, developing, manufacturing, and commercializing drugs for the cure of various kinds of diseases. The company is doing research and production in many nations and 120 countries are using its products.
Eli Lilly Generated handsome revenue in 2020 through the sales of its top products which include Trulicity (Diabetes medicine), Basaglar (Insulin product), and Jardiance (Oral Diabetes drug). Trulicity generated $3.6 billion revenue in the first three quarters of 2020 with a rise of 22%. Similarly, Basaglar generated 842$ million revenue with a rise of 5% and Jardiance showed a rise of 24% with 840$ million income.
The company has got positive results in phase 2 clinical trial of one of its potential drugs for Alzheimer’s disease called donanemab. More than 5 Million Alzheimer’s patients exist in the U.S and still, there is no approved drug for the cure. Still, donanemab has a long way to go for approval but investors can monitor its progress.
The company reported on Tuesday that its late-stage coronavirus treatment trial which includesBamlanivimab (LY-CoV555) 2800 mg and Etesevimab (LY-CoV016), has reduced the riskof death in serious patients and hospitalization by 70% which is pointing out the bright future of the company and investors in terms of revenue.
Hence Lilly has a good chance to outperform in the future due to its revenue growth, solid stock price performance, and good cash flow from operations.
Teladoc Health Inc (NYSE:TDOC)
Teladoc Health, Inc. (TDOC) is a virtual healthcare company playing a lead role in providing the services of diagnosis, treatment recommendation, and prescription through mobile phones and video consultations. The current pandemic situation is suitable for the company when people do not bother to go out of their homes unnecessarily. The company is getting fame day by day due to its best virtual health care services in remote areas and attracting institutional investors to invest in it.
Though Teladoc has not revealed the 2020 report but rough estimates show that it has now more than 50 million members, facilitated more than 10 million visits, and generated about 1.1$ billion revenue in 2020 which is almost double than the previous year. Currently, many companies are providing Teladoc’s health care services to their employees which is expecting to grow in the future. Teladoc’s recent acquisition of Lovingo Health is also creating a more positive vibe for investors.
CVS Health Corp (NYSE:CVS)
CVS Health Corporation (CVS) is an integrated pharmacy healthcare service provider company. It offers pharmacy benefit management plans, health plans, prescription drug plans, and serves the government as well as private employees of many companies. It possesses nearly 10000 drug stores and1100 Minute Clinics in the U.S.The company is playing a key role in COVID-19 testing and is contributing a lot in the vaccination campaign as it has performed nearly 10 million coronavirus tests and 700,000 vaccinations. The company is currently handling 10% of coronavirus vaccination in the U.S and can vaccinate 25 million people per month.
CVS is not just relying on COVID vaccination but also fighting against influenza by vaccinating people. The company generated $67 billion in the 3rd quarter of 2020 with a rise of 3.5% in its sales. Moreover, the company possesses more than 23 million health insurance members nationwide. Thanks to Aetna, a CVS subsidiary, which generates more than $18.5 billion per quarter in health insurance fees.
The company is currently in a good position and has ample profit to sustain its dividend. Its shares are expecting to outperform in 2021 due to active participation in COVID-19 vaccination in the U.S.It can be a good choice for dividend as well as growth investors.